What price per share was used for the tax-withholding shares in the XERS Form 4?

The withheld shares were valued at a transaction price of $8.08 per share for the 21,918 Xeris Biopharma shares used to satisfy income tax and withholding obligations.

Xeris COO has 21,918 shares withheld for taxes

Q: What transaction did Kevin McCulloch report in this Form 4 for XERS?

Kevin McCulloch reported that 21,918 Xeris Biopharma (XERS) shares of common stock were withheld by the company on August 1, 2026 to cover income tax and withholding obligations arising from vested restricted stock units.

Q: Was the XERS Form 4 transaction an open-market sale by Kevin McCulloch?

No. The Form 4 states the transaction was a tax-withholding disposition, where 21,918 shares were withheld by Xeris Biopharma to satisfy income tax and withholding and remittance obligations tied to vested restricted stock units.

Q: Does Kevin McCulloch report any indirect ownership of XERS shares?

Yes. The Form 4 reports 25,000 XERS shares held indirectly “By Spouse”, and states that McCulloch disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Q: Was the XERS Form 4 transaction under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan, and the footnotes describe the event as shares withheld for tax obligations on vested restricted stock units.

Xeris Biopharma Holdings, Inc. (XERS) reported an insider equity-tax event by President and Chief Operating Officer Kevin McCulloch.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. (XERS) reported an insider equity-tax event by President and Chief Operating Officer Kevin McCulloch. On August 1, 2026, 21,918 shares of common stock were withheld by the company at $8.08 per share to satisfy income tax and withholding obligations on vested restricted stock units. After this tax-withholding disposition, McCulloch directly held 1,654,208 shares of common stock. An additional 25,000 shares are reported as indirectly owned by his spouse, with McCulloch disclaiming beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Tax Withholding: 21,918 shares

Tax Withholding 2 txns

Insider McCulloch Kevin

Role See Remarks

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock ^F1	21,918	$8.08	$177K
holding	Common Stock ^F2	--	--	--

Holdings After Transaction: Common Stock — 1,654,208 shares (Direct); Common Stock — 25,000 shares (Indirect, By Spouse)

Footnotes (2)

F1. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026.
F2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

Shares withheld for tax obligations: 21,918 shares Tax-withholding price per share: $8.08 per share Direct holdings after transaction: 1,654,208 shares +2 more

5 metrics

Shares withheld for tax obligations 21,918 shares Common stock withheld on August 1, 2026 to satisfy income tax and withholding obligations on vested RSUs

Tax-withholding price per share $8.08 per share Valuation for 21,918 withheld common shares used to satisfy tax obligations

Direct holdings after transaction 1,654,208 shares Common stock directly owned by Kevin McCulloch following the August 1, 2026 transaction

Indirect holdings by spouse 25,000 shares Common stock indirectly owned, reported as held "By Spouse" with beneficial ownership disclaimed except for pecuniary interest

Exercise price or tax-liability related shares 21,918 shares Shares reported in code F transaction for payment of tax liability by delivering or withholding securities

Key Terms

net settlement, restricted stock units, pecuniary interest

3 terms

net settlement financial

"in connection with the net settlement of restricted stock units vested"

restricted stock units financial

"in connection with the net settlement of restricted stock units vested"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

pecuniary interest financial

"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Kevin McCulloch report in this Form 4 for XERS?

Kevin McCulloch reported that 21,918 Xeris Biopharma (XERS) shares of common stock were withheld by the company on August 1, 2026 to cover income tax and withholding obligations arising from vested restricted stock units.

Was the XERS Form 4 transaction an open-market sale by Kevin McCulloch?

No. The Form 4 states the transaction was a tax-withholding disposition, where 21,918 shares were withheld by Xeris Biopharma to satisfy income tax and withholding and remittance obligations tied to vested restricted stock units.

How many XERS shares does Kevin McCulloch hold directly after this transaction?

Following the August 1, 2026 tax-withholding transaction, Kevin McCulloch is reported as directly owning 1,654,208 shares of Xeris Biopharma common stock.

Does Kevin McCulloch report any indirect ownership of XERS shares?

Yes. The Form 4 reports 25,000 XERS shares held indirectly “By Spouse”, and states that McCulloch disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Was the XERS Form 4 transaction under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan, and the footnotes describe the event as shares withheld for tax obligations on vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/21/2026 - 04:16 PM EDT Accepted by SEC EDGAR 08/21/2026 - 04:15 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCulloch Kevin

(Last)

(First)

(Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO

ILLINOIS

60607

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/01/2026		F		21,918⁽¹⁾	D	$8.08	1,654,208	D
Common Stock								25,000⁽²⁾	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026.

2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer

	/s/ Beth Hecht, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR